repeat dose study
Recently Published Documents


TOTAL DOCUMENTS

14
(FIVE YEARS 0)

H-INDEX

5
(FIVE YEARS 0)

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Courtney Crim ◽  
Mark Gotfried ◽  
Selwyn Spangenthal ◽  
Michael Watkins ◽  
Amanda Emmett ◽  
...  

2019 ◽  
Vol 16 (1) ◽  
pp. 96-103
Author(s):  
Tielle Moraes de Almeida ◽  
Gilsane Lino von Poser ◽  
Liz Girardi Müller ◽  
Paula Reis Pereira ◽  
Eduardo Cassel ◽  
...  

Background:Species of Valeriana show sedative, hypnotic, anxiolytic, antidepressant and anti-inflammatory properties, which are associated with valepotriates. However, data about toxicity and safety of these compounds are still limited. The aim of this study was to investigate the toxicity of a valepotriate-enriched fraction (VAL) from Valeriana glechomifolia Meyer based on the Organization for Economic Cooperation and Development (OECD) guidelines 423 and 407.Methods:In the acute study, CF1 mice were treated with a single dose of VAL (2000 mg/kg, p.o.) and observed for 14 days. In the repeated dose study, CF1 mice received single daily doses of VAL (30, 150 or 300 mg/kg, p.o.) or vehicle for 28 days. These doses were chosen based on previous results by our group and according to Guideline 407- OECD.Results:The acute study allowed to classify VAL in the hazard category 5. The repeat-dose study has shown that VAL 300 mg/kg delayed weight gain and reduced food consumption in the first week, probably due to transient sedative effects. The other doses had no effect on animals’ ponderal evolution. At the end of the treatment, all groups had equal body weight and food consumption. None of the doses altered any behavioral, urinary, biochemical, hematological, anatomic or histological parameters.Conclusion:A valepotriate-enriched fraction from Valeriana glechomifolia presents relatively low oral acute toxicity and does not induce evident toxicity after oral repeated treatment (at least up to 300 mg/kg) in mice.<P&gt;


2018 ◽  
Vol 37 (6) ◽  
pp. 422-433 ◽  
Author(s):  
David V. Gauvin ◽  
Zachary J. Zimmermann ◽  
Joshua Yoder ◽  
Theodore J. Baird

Spontaneous unexpected events occasionally develop during the course of rodent preclinical toxicology studies. The presentation of serious adverse events on animal studies may require notification of these events to the Food and Drug Administration if the events are most likely the direct result of test article administration. Classical conditioning of emotional responses may occur over the course of a repeat-dose study and clinical observation calls of “convulsions” are reported to the study director and/or staff veterinarians. In the current heightened environment of most research laboratories related to general animal welfare issues, it is imperative to have an action plan that will help to elucidate the potential origins of these motor events. We provide 10 factors that should be considered to help the study director determine the most likely cause of these motor attacks as being organic or psychogenic in origin.


2015 ◽  
Vol 114 (2) ◽  
pp. S125-S126
Author(s):  
Melissa P. Wasserstein ◽  
Simon A. Jones ◽  
Handrean Soran ◽  
George Diaz ◽  
Natalie Lippa ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document